靶向CD371并分泌白细胞介素-18的CAR-T细胞表现出强劲扩增并清除难治性急性髓系白血病
在淋巴系统恶性肿瘤中取得成功的嵌合抗原受体(CAR)T细胞疗法尚未在急性髓系白血病(AML)中重现。研究者开发了靶向CD371、携带突变CD28共刺激域以减少T细胞耗竭并组成性分泌白细胞介素-18(IL-18)以增强免疫功能的CAR-T细胞(CD371/SAVVY/IL-18 CAR),并启动1期试验(NCT06017258),在5例复发/难治性AML患者中成功制备并回输,单次输注3×10^4或3×10^5个CAR-T细胞/kg后观察到扩增;3例对≥5线治疗难治且异基因移植后患者实现AML清除且无移植物抗宿主病证据。
要点
- CD371/SAVVY/IL-18 CAR-T细胞在5例复发/难治性AML患者中成功制备并回输。
- 单次输注3×10^4或3×10^5个CAR-T细胞/kg后观察到CAR-T细胞扩增。
- 3例对≥5线治疗难治且异基因移植后患者实现AML清除且无移植物抗宿主病证据。
核心结论
- 这项先导研究凸显低剂量IL-18「装甲」CAR-T细胞对难治性AML具有活性,并可能促进CAR-T细胞毒性和内源性先天抗肿瘤免疫。
研究设计与样本
- 1期试验(NCT06017258),在5例复发/难治性AML患者中制备并回输CD371/SAVVY/IL-18 CAR-T细胞。
主要发现
- 单次输注3×10^4或3×10^5个CAR-T细胞/kg后观察到CAR-T细胞扩增。
- 3例对≥5线治疗难治且异基因移植后患者实现AML清除且无移植物抗宿主病证据。
- 接受3×10^5个CAR-T细胞/kg的2例患者出现剂量限制性毒性(伴骨髓发育不良的持续性血细胞减少;重度细胞因子释放综合征),随后3例患者剂量降至3×10^4个CAR-T细胞/kg。
- 单细胞分析显示,回输后2周应答者循环CAR-T细胞主要为细胞毒性CD8+效应T细胞,同时存在的自然杀伤(NK)细胞表达活化标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Success of chimeric antigen receptor (CAR) T-cell therapy in lymphoid malignancies has not yet been recapitulated in acute myeloid leukemia (AML). We developed CAR T cells targeting CD371 with a mutated CD28 costimulatory domain to limit T-cell exhaustion, and constitutive interleukin-18 (IL-18) secretion to enhance immune function (CD371/SAVVY/IL-18 CAR). We initiated a phase 1 trial (NCT06017258), successfully manufactured and administered CD371/SAVVY/IL-18 CAR T cells in 5 patients with relapsed/refractory AML and observed expansion following a single infusion of 3 × 104 or 3 × 105 CAR T cells per kg; 3 patients refractory to ≥5 lines of therapy and postallogeneic transplant exhibited AML clearance and no evidence of graft-versus-host disease. Dose-limiting toxicity in the 2 patients treated with 3 × 105 CAR T cells per kg dose (prolonged cytopenias with marrow hypoplasia; severe cytokine release syndrome) led to dose reduction to 3 × 104 CAR T cells per kg in the following 3 patients. Single-cell analyses revealed that circulating CAR T cells in responders included predominantly cytotoxic CD8+ effector T cells 2 weeks after infusion while coexisting natural killer (NK) cells expressed markers of activation. This pilot study highlights the activity of low-dose IL-18 "armored" CAR T cells against refractory AML and their potential to promote CAR T-cell cytotoxicity and innate endogenous antitumor immunity. This trial was registered at www.ClinicalTrials.gov as #NCT06017258.
引用
- Geyer MB, DeWolf S, Mi X, et al. CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. Blood. 2025. PMID: 40864984. doi:10.1182/blood.2025029532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。